Thermo Fisher Scientific Inc., which has offices in Finland, and Samsung Electronics Co., Ltd., have formed a strategic collaboration to jointly design, develop and market better point-of-care (POC) solutions in key applications. These include the detection of sepsis, drug abuse and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.

“Samsung has developed a compelling and innovative suite of POC platforms,” said Marc Tremblay, Ph.D., president of Thermo Fisher’s clinical diagnostics business. “We look forward to working with Samsung to add some of our leading biomarkers and assays to their platforms to create a truly differentiated testing menu.”

“We are very excited to leverage Thermo Fisher Scientific’s strong commercial sales and service channels, as well as the potential to offer a broader range of tests to our customers and their patients,” said Soo-In Cho, president and head of the health and medical equipment business at Samsung. “This strategic collaboration combines the strengths of two industry leaders to accelerate POC innovation and more rapidly bring solutions to market.”